Compugen Reports Third Quarter 2025 Results: Earnings Beat, Clinical Progress, and Cash Runway Extended

Compugen reported third quarter 2025 revenue of approximately $1.9 million, beating analyst estimates of $1.5 million—a 26% positive surprise156.

Net loss for Q3 2025 was about $6.98 million, or $0.07 per share, which was narrower than anticipated and improved compared to consensus expectations of a $0.09 loss per share356.

Despite the smaller loss, revenue declined from $17.1 million in Q3 2024, reflecting decreased upfront and milestone payment recognition from the Gilead license agreement6.

Compugen maintained a strong financial position with $86.1 million in cash and equivalents as of September 30, 2025, expecting its cash runway to fund operations into Q3 20276.

Research and development expenses for the quarter were $5.8 million, down from $6.3 million in the same period last year; general and administrative expenses were $2.2 million versus $2.6 million in Q3 20246.

Clinical progress included:
Phase 1 data for COM701 (anti-PVRIG) presented at ESMO 2025; ongoing MAIA-ovarian platform trial with interim analysis estimated for Q1 2027; and the Phase 1 trial design for GS-0321 (COM503), licensed to Gilead, shared at SITC 20256.

Partner AstraZeneca presented promising results for rilvegostomig in two Phase 2 trials (NSCLC and bladder cancer) at ESMO 20256.

Following the Q3 earnings release, Compugen's stock rose significantly in pre-market trading due to positive financial surprises and strong operational updates1.

Sources:

1. https://www.chartmill.com/news/CGEN/Chartmill-37462-Compugen-Ltd-NASDAQCGEN-Reports-Q3-2025-Earnings-Beat-Stock-Rises

3. https://www.insidermonkey.com/blog/compugen-ltd-nasdaqcgen-q3-2025-earnings-call-transcript-1643532/

5. https://www.indexbox.io/blog/compugen-reports-third-quarter-2025-financial-results/

6. https://www.prnewswire.com/news-releases/compugen-reports-third-quarter-2025-results-302610022.html